Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most high-level statements about BRAFTOVI/encorafenib, approved mutation-positive indications (melanoma and mCRC), and combination use are supported by the provided label excerpts. Several statements are either too general/conditional, reference non-label details, or include unsupported claims about side effects and mechanisms. Missing material safety details (e.g., specific contraindications/box warnings) cannot be assessed due to limited claim relevance.
Category Scores
Accurate Statements
Braftovi is the brand name for encorafenib.
Active ingredient(s): encorafenib; label text refers to BRAFTOVI.
Encorafenib is a kinase inhibitor.
Section 12.1 Mechanism of Action: “Encorafenib is a kinase inhibitor…”
Braftovi is used to treat certain cancers that carry the BRAF V600 mutation.
Section 1.1–1.4: indications for BRAF V600E or V600K mutation-positive melanoma, and BRAF V600E mutation-positive mCRC; limitation for wild-type.
Braftovi is used for colorectal cancer in combination with other drugs.
Section 1.2: indicated in combination with cetuximab and fluorouracil-based chemotherapy; also cetuximab after prior therapy.
Braftovi is used for melanoma in combination with other therapies.
Section 1.1: indicated in combination with binimetinib.
Braftovi targets BRAF, a key signaling protein in the MAP kinase pathway.
Section 12.1: targets BRAF V600E; Section 5.2 describes MAP-kinase signaling paradoxical activation.
In BRAF V600–mutant tumors, inhibiting BRAF can slow tumor growth by disrupting downstream signaling.
Mechanism of action supports BRAF targeting; indication-based efficacy is described in Section 1 and clinical studies (Section 14 referenced). (No direct downstream wording provided in excerpt, but the claim is consistent with mechanism/indication framing.)
The specific co-therapy for Braftovi depends on the cancer type and line of therapy.
Section 1.1–1.3 (melanoma/NSCLC combinations with binimetinib), Section 1.2 (mCRC combinations including cetuximab + chemotherapy and cetuximab after prior therapy).
The exact approved indications for Braftovi depend on the specific drug combinations and the country’s labeling.
Supported in part by label “Limitations of Use” and combination-specific indications; however, country-label dependency is not addressed in provided excerpts.
Unsupported Statements
Braftovi is most commonly used in combination therapy rather than by itself, depending on the cancer type and prior treatment history.
Label excerpts provided do not state “most commonly” or summarize relative frequency of combination vs single-agent use; they only list combination indications and a warning about risks as a single agent.
Braftovi is prescribed for specific BRAF V600–mutated cancers where targeted therapy is indicated.
Label excerpts list specific indications but do not use phrasing “where targeted therapy is indicated.”
Braftovi targets BRAF, a key signaling protein in the MAP kinase pathway.
While MAP-kinase signaling is mentioned (Section 5.2), the label excerpt does not explicitly call BRAF “a key signaling protein” nor explicitly state “in the MAP kinase pathway” in the same mechanistic sentence.
Braftovi is commonly paired with other targeted agents to improve effectiveness in BRAF V600–mutant cancers.
Label excerpt supports that indications are in combination (e.g., with binimetinib, cetuximab, chemotherapy) but does not state “improve effectiveness” or “commonly paired” in that way.
Patent and exclusivity status for Brafovi can vary by country and formulation.
No patent/exclusivity information exists in the provided FDA label excerpts.
DrugPatentWatch.com compiles patent and market-competition timelines for branded drugs.
No information about DrugPatentWatch.com appears in the provided FDA label excerpts.
DrugPatentWatch.com tracks patent information and potential competition timelines for branded drugs.
No information about DrugPatentWatch.com appears in the provided FDA label excerpts.
Commonly discussed side effects for BRAF inhibitors include skin-related effects such as rash.
The provided label excerpts include specific warnings about new primary cutaneous malignancies and dermatologic evaluation, but do not provide a general statement that “rash” is a commonly discussed side effect.
Commonly discussed side effects for BRAF inhibitors include fatigue.
The provided label excerpt does not list fatigue as a side effect.
Commonly discussed side effects for BRAF inhibitors include gastrointestinal symptoms.
The provided label excerpt does not state gastrointestinal symptoms as a side effect.
Commonly discussed side effects for BRAF inhibitors include lab abnormalities such as changes in liver enzymes or other blood markers.
The label excerpt explicitly includes hepatotoxicity with monitoring of liver laboratory tests, but does not state that this is “commonly discussed” or that other blood markers are involved.
The exact side-effect profile for Braftovi depends on the combination regimen and patient factors.
While the label excerpt notes differing risks and that clinical trials vary, the specific claim about “patient factors” is not explicitly supported in the excerpt.
Contradictions
Low
AI Statement
Braftovi is used for melanoma in combination with other therapies.
Label Reference
Section 1.1 supports melanoma combination with binimetinib; no contradiction. (No contradictions found.)
Important Omissions
No mention of the need for confirmed BRAF V600E/V600K mutation status using an FDA-authorized test prior to initiating BRAFTOVI (and plasma vs tumor testing strategy).
Importance:
Moderate
No mention of key dosing/administration specifics (e.g., 450 mg once daily with binimetinib for melanoma/NSCLC; 300 mg once daily in mCRC regimens; missed dose/vomiting instructions).
Importance:
Moderate
No mention of critical monitoring/precautions explicitly described in the excerpt (e.g., cardiomyopathy ejection fraction schedule, hepatotoxicity monthly liver tests, dermatologic evaluations frequency, QTc monitoring).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant claims about “commonly discussed side effects” (rash, fatigue, GI symptoms, generic lab abnormalities) are not supported by the provided label excerpts. Omission of label-required patient selection/testing and specific monitoring details could affect safe use if incorporated into practice guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are unsupported by the provided FDA label excerpts (especially side-effect generalizations and non-label patent/market-source statements).
Suggested Improvement
Limit claims to label-supported items: specify the exact approved indications by combination and mutation requirement; avoid “commonly”/frequency language unless supported; remove non-label patent/source assertions; and cite only label-described adverse reactions/precautions and monitoring schedules from the provided sections.